Social Media Ideas for Moderna

Moderna flu vaccine wins unanimous support from FDA panel

The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.

Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells

Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune d...

Moderna’s flu candidate sails through FDA advisory committee in unanimous votes

As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its bid to expand the reach of its mRNA platform to the massive influenza...

Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

Amid a raging Ebola outbreak, officials "urgently accelerate development" of vaccines.

Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investi...

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026

Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028

Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease FranchisesEster Banqu...

Moderna and other groups get $60 million to develop Ebola vaccine

Moderna: Flu Vaccine Progress Is Only Part Of The Story

<![CDATA[Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profil...

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Va...

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The INTERCEPT-Lynch trial is part of a scientific collaboration b...

FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

In February, a Trump official refused to review the vaccine.

mRNA Flu Vaccine Shows Stronger, Longer-Lasting Immune Response

Moderna’s investigational mRNA flu vaccine generated broader, longer-lasting immune responses than a standard flu shot, potentially improving protection against evolving influenza...

Moderna to Host Investor Event - Science Day

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling

With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’...

Inside the race to develop a new Ebola vaccine

As Ebola rages, Moderna and others are racing to develop an mRNA vaccine for the rare Bundibugyo virus driving the current outbreak

FDA panel backs first-of-its-kind flu vaccine using mRNA technology

The Food and Drug Administration is evaluating Moderna's new shot, dubbed mFlusiva, for older Americans ahead of the winter flu season.

Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science

mRNA Flu Vaccine Provides Broad Immune Defense Against Diverse Influenza Strains

A groundbreaking new study conducted by researchers at Washington University School of Medicine in St. Louis illuminates the promising potential of an investigational mRNA influenz...

Breaking: Moderna’s mRNA Flu Vaccine Gets Unanimous Thumbs-Up Despite Risks, Low Efficacy

The FDA’s Vaccines and Related Biological Products Advisory Committee today voted 9-0 to recommend approval of Moderna’s mRNA flu vaccine for the 50-64 and 65-plus age groups. Karl...

Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

<![CDATA[FDA Files Concerns Over Missing Data for Moderna’s mRNA Flu Shot: Report ]]>

Moderna Says New COVID Vax Doesn't Infringe BioNTech IP

Moderna has pushed back at BioNTech's patent infringement lawsuit accusing its newer COVID-19 vaccine of exploiting BioNTech's own technology, saying that it never infringed and th...

A Better Flu Vaccine

by Gertrud U. Rey On June 18, 2026, the top advisory committee for the Food and Drug Administration (FDA) unanimously recommended Moderna’s new mRNA influenza vaccine, mRNA‑1010 (m...